Blueprint Medicines Takes $40MM From Third Rock To Build Oncology Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
Incubated for months within TRV, the Boston-area startup aims to discover highly specific cancer drugs for personalized medicine.
You may also be interested in...
Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators
Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.
Third Rock Pumps $41 Million Into Global Blood Therapeutics
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.
Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million
The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.